Anti-remodeling potencies of the soluble guanylate cyclase activator BAY 41-2272 in human lung fibroblasts

C. Lambers, M. Roth, E. Hofbauer, V. Petkov, L. H. Block (Vienna, Austria; Basel, Switzerland)

Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH
Session: Pulmonary hypertension: improving treatment in PAH
Session type: Oral Presentation
Number: 3423
Disease area: Interstitial lung diseases, Pulmonary vascular diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Lambers, M. Roth, E. Hofbauer, V. Petkov, L. H. Block (Vienna, Austria; Basel, Switzerland). Anti-remodeling potencies of the soluble guanylate cyclase activator BAY 41-2272 in human lung fibroblasts. Eur Respir J 2014; 44: Suppl. 58, 3423

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Treprostinil prodrugs for pulmonary arterial hypertension evaluated in cAMP profiling studies in live CHO-K1 cells
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014

Prevention of monocrotaline-induced pulmonary vascular and myocardial remodeling by the selective neutrophil elastase inhibitor BAY 85-8501
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014

Acid sphingomyelinase, a novel pathway for pulmonary vasoconstriction. Activation by apoptotic T cell microparticles and Fas ligand
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014

Anti-contractile and anti-proliferative responses in human pulmonary arterial smooth muscle cells induced by ACT-333679, the active metabolite of selexipag, a non-prostanoid selective prostacyclin receptor agonist
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014

Obligatory role of MEK/ERK/RSK90 in the mitogenic responses of human pulmonary artery smooth muscle cells
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014

Selective inhibition of neutrophil elastase by BAY 85-8501 improves exercise capacity and pulmonary hypertension in a porcine pancreatic elastase-induced emphysema model
Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH
Year: 2014

Nuclear factor-kappa B inhibition exerts anti-remodelling effects in pulmonary arterial smooth muscle cells
Source: International Congress 2014 – Pathobiology of pulmonary hypertension
Year: 2014

A soluble guanylate cyclase stimulator, BAY 41-8543, preserves pulmonary artery endothelial function in experimental pulmonary embolism
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013


PKCalpha deficiency in mice is associated with pulmonary vascular hyperresponsiveness to thromboxane A2 via increased TXA2 receptor expression
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014

Nuclear IL-33 arguments ST2 receptor expression in pulmonary arterial endothelial cells: Implication in the pathogenesis and progression of pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014

Neuron-derived orphan receptor 1 mediated human pulmonary arterial smooth muscle cells proliferation via cyclin D1
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014


M2 macrophages derived from patients with idiopathic pulmonary arterial hypertension are susceptible for apelin-mediated suppression of pro-inflammatory cytokines
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014

MicroRNA-155 controls pulmonary artery fibroblast cell signalling and proliferation in a knockout mouse model: A role in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014

Role of NMDA receptors in vascular remodelling associated to pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014

Derivation and characterisation of endothelial cells from patients with chronic thromboembolic pulmonary hypertension
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014

Modulation of symmetric dimethyarginine formation by apelin in human pulmonary endothelial cells
Source: International Congress 2015 – Translational research in respiratory care: new findings
Year: 2015

The role of anion exchanger on pulmonary vascular response to sustained alveolar hypoxia in the isolated perfused rabbit lung
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014


ASK1 promotes maladaptive remodeling in a rodent model of pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014

Oral delivery of transplastomic plant derived angiotensin converting enzyme2 - a novel approach for pulmonary hypertension therapeutics
Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH
Year: 2014

Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013